Warning: The NCBI web site requires JavaScript to function. more...
Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X, Bikfalvi A, Martuza RL, Kurtz A, Rabkin SD.
Clin Cancer Res. 2006 Nov 15;12(22):6791-9.PMID: 17121900 [PubMed - indexed for MEDLINE]Related articlesFree article
Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector.
Kuroda T, Rabkin SD, Martuza RL.
Cancer Res. 2006 Oct 15;66(20):10127-35.PMID: 17047077 [PubMed - indexed for MEDLINE]Related articlesFree article
Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Martuza RL, Rabkin SD, Kurtz A.
Mol Ther. 2006 Dec;14(6):789-97. Epub 2006 Oct 10.PMID: 17045531 [PubMed - indexed for MEDLINE]Related articles
Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases.
Kuroda T, Martuza RL, Todo T, Rabkin SD.
BMC Biotechnol. 2006 Sep 22;6:40.PMID: 16995942 [PubMed - indexed for MEDLINE]Related articlesFree article
Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung.
Varghese S, Rabkin SD, Nielsen PG, Wang W, Martuza RL.
Clin Cancer Res. 2006 May 1;12(9):2919-27.PMID: 16675589 [PubMed - indexed for MEDLINE]Related articlesFree article
Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
Varghese S, Rabkin SD, Liu R, Nielsen PG, Ipe T, Martuza RL.
Cancer Gene Ther. 2006 Mar;13(3):253-65.PMID: 16179929 [PubMed - indexed for MEDLINE]Related articles
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on
» See more...